Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
43.3 EUR | +0.81% | +7.98% | -4.94% |
Apr. 29 | STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank reiterates its Neutral rating | ZD |
Apr. 26 | STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
Weaknesses
- The firm trades with high earnings multiples: 26.24 times its 2024 earnings per share.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.94% | 563M | B+ | ||
+7.26% | 217B | B | ||
+6.08% | 183B | B- | ||
+9.68% | 131B | B- | ||
+23.81% | 106B | A- | ||
-0.95% | 62.16B | A- | ||
+9.94% | 51.02B | B+ | ||
+4.81% | 50.89B | B+ | ||
-1.54% | 40.16B | A | ||
+0.75% | 34.79B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SBS Stock
- Ratings Stratec SE